Amedeo Smart

Free Medical Literature Service


 

Amedeo

Influenza

  Free Subscription

Articles published in
Drug Saf
    March 2024
  1. DOS SANTOS G, Devadiga R, Kim CS, Bang J, et al
    An 8-Year Prospective, Observational, Multi-centre Post-Marketing Safety Surveillance Study Conducted in South Korea (2014-2022) Following the Introduction of GSK's Inactivated Quadrivalent Seasonal Influenza Vaccine (Fluarix Tetra) for Subjects Aged
    Drug Saf. 2024 Mar 14. doi: 10.1007/s40264-024-01395.
    >> Share

  2. WYSZYNSKI DF, Papageorghiou AT, Renz C, Metz TD, et al
    The COVID-19 International Drug Pregnancy Registry (COVID-PR): Protocol Considerations.
    Drug Saf. 2024;47:195-204.
    >> Share

    February 2024
  3. MORO PL, Ennulat C, Brown H, Woody G, et al
    Safety of Simultaneous Administration of Bivalent mRNA COVID-19 and Influenza Vaccines in the Vaccine Adverse Event Reporting System (VAERS).
    Drug Saf. 2024 Feb 27. doi: 10.1007/s40264-024-01406.
    >> Share

  4. QIN SX, Cheng FWT, Kwok WC, Fung LWY, et al
    Effectiveness and Respiratory Adverse Events Following Inactivated and mRNA COVID-19 Vaccines in Patients with COPD and Asthma: A Chinese Population-Based Study.
    Drug Saf. 2024;47:135-146.
    >> Share

  5. DONG G, Bate A, Haguinet F, Westman G, et al
    Optimizing Signal Management in a Vaccine Adverse Event Reporting System: A Proof-of-Concept with COVID-19 Vaccines Using Signs, Symptoms, and Natural Language Processing.
    Drug Saf. 2024;47:173-182.
    >> Share

    December 2023
  6. DE GERMAY S, Singier A, Salvo F, Pariente A, et al
    Impact of Covid-19 Vaccination on Spontaneous Pharmacovigilance Reporting in France.
    Drug Saf. 2023;46:1381-1389.
    >> Share

    November 2023
  7. MICALLEF B, Dogne JM, Sultana J, Straus SMJM, et al
    An Exploratory Study of the Impact of COVID-19 Vaccine Spontaneous Reporting on Masking Signal Detection in EudraVigilance.
    Drug Saf. 2023;46:1089-1103.
    >> Share

    October 2023
  8. SLINGERLAND P, van Hunsel FPAM, Lieber T, van Balveren L, et al
    The Effect of Sex on the Incidence, Latency, Duration and Perceived Burden of Adverse Events Following Seasonal Influenza Vaccination in the Netherlands.
    Drug Saf. 2023 Oct 26. doi: 10.1007/s40264-023-01356.
    >> Share

    September 2023
  9. WALTON M, Pletzer V, Teunissen T, Lumley T, et al
    Adverse Events Following the BNT162b2 mRNA COVID-19 Vaccine (Pfizer-BioNTech) in Aotearoa New Zealand.
    Drug Saf. 2023;46:867-879.
    >> Share

    June 2023
  10. KAUR U, Fatima Z, Maheshwari K, Sahni V, et al
    Long-Term Safety Analysis of the ChAdOx1-nCoV-19 Corona Virus Vaccine: Results from a Prospective Observational Study in Priority Vaccinated Groups in North India.
    Drug Saf. 2023;46:553-563.
    >> Share

  11. AHMADIZAR F, Luxi N, Raethke M, Schmikli S, et al
    Safety of COVID-19 Vaccines Among the Paediatric Population: Analysis of the European Surveillance Systems and Pivotal Clinical Trials.
    Drug Saf. 2023;46:575-585.
    >> Share

    May 2023
  12. KRALOVA K, Wilson CA, Richebourg N, D'souza J, et al
    Quality of MedDRA((R)) Coding in a Sample of COVID-19 Vaccine Medication Error Data.
    Drug Saf. 2023;46:501-507.
    >> Share

    April 2023
  13. BAUCHAU V, Davis K, Frise S, Jouquelet-Royer C, et al
    Real-World Monitoring of COVID-19 Vaccines: An Industry Expert View on the Successes, Challenges, and Future Opportunities.
    Drug Saf. 2023;46:327-333.
    >> Share

  14. RAETHKE M, van Hunsel F, Thurin NH, Dureau-Pournin C, et al
    Cohort Event Monitoring of Adverse Reactions to COVID-19 Vaccines in Seven European Countries: Pooled Results on First Dose.
    Drug Saf. 2023;46:391-404.
    >> Share

  15. OGAR CK, Quick J, Gilbert HN, Vreman RA, et al
    Adverse Events to SARS-CoV-2 (COVID-19) Vaccines and Policy Considerations that Inform the Funding of Safety Surveillance in Low- and Middle-Income Countries: A Mixed Methods Study.
    Drug Saf. 2023;46:357-370.
    >> Share

    March 2023
  16. KALKNER KM, Sundstrom A, Nurminen ML, Larsson M, et al
    Optimizing Safety Surveillance for COVID-19 Vaccines at the Swedish Medical Products Agency.
    Drug Saf. 2023;46:319-321.
    >> Share

  17. WYSZYNSKI DF, Bhattacharya M, Martinez-Perez O, Scialli AR, et al
    The COVID-19 Vaccines International Pregnancy Exposure Registry (C-VIPER): Protocol and Methodological Considerations.
    Drug Saf. 2023;46:297-308.
    >> Share

  18. ZAPATA-CACHAFEIRO M, Prieto-Campo A, Portela-Romero M, Carracedo-Martinez E, et al
    Effect of Previous Anticoagulant Treatment on Risk of COVID-19.
    Drug Saf. 2023;46:273-281.
    >> Share

    February 2023
  19. DIAK IL, Swank K, McCartan K, Beganovic M, et al
    The Food and Drug Administration's (FDA's) Drug Safety Surveillance During the COVID-19 Pandemic.
    Drug Saf. 2023;46:145-155.
    >> Share

    January 2023
  20. OOSTERHUIS I, Scholl J, van Puijenbroek E, Kant A, et al
    Optimizing Safety Surveillance for COVID-19 Vaccines at the National Pharmacovigilance Centre Lareb: One Year of COVID-19 Vaccine Experience.
    Drug Saf. 2023;46:65-75.
    >> Share

    December 2022
  21. WAN EYF, Chui CSL, Mok AHY, Xu W, et al
    mRNA (BNT162b2) and Inactivated (CoronaVac) COVID-19 Vaccination and Risk of Adverse Events and Acute Diabetic Complications in Patients with Type 2 Diabetes Mellitus: A Population-Based Study.
    Drug Saf. 2022;45:1477-1490.
    >> Share

    October 2022
  22. KAUR U, K L A, Chauhan M, Joshi A, et al
    A Prospective Observational Study on BBV152 Coronavirus Vaccine Use in Adolescents and Comparison with Adults: Interim Results of the First Real-World Safety Analysis.
    Drug Saf. 2022;45:1099-1109.
    >> Share

    September 2022
  23. LANE S, Shakir S
    Assessing Case Fatality on Cases of Thrombosis with Concurrent Thrombocytopenia Following COVID-19 Vaccine AstraZeneca (Vaxzevria) in the United Kingdom: A Review of Spontaneously Reported Data.
    Drug Saf. 2022;45:1003-1008.
    >> Share

    August 2022
  24. KANT A, van Hunsel F
    Authors' Reply to Mungmunpuntipantip et al.'s Comment on "Description of Frequencies of Reported Adverse Events Following Immunization Among Four Different COVID-19 Vaccine Brands".
    Drug Saf. 2022;45:925-926.
    >> Share

  25. MUNGMUNPUNTIPANTIP R, Wiwanitkit V
    Comment on "Description of Frequencies of Reported Adverse Events Following Immunization Among Four Different COVID-19 Vaccine Brands".
    Drug Saf. 2022;45:923.
    >> Share

    July 2022
  26. HARPAZ R, DuMouchel W, Van Manen R, Nip A, et al
    Signaling COVID-19 Vaccine Adverse Events.
    Drug Saf. 2022;45:765-780.
    >> Share

    June 2022
  27. SHOAIBI A, Rao GA, Voss EA, Ostropolets A, et al
    Phenotype Algorithms for the Identification and Characterization of Vaccine-Induced Thrombotic Thrombocytopenia in Real World Data: A Multinational Network Cohort Study.
    Drug Saf. 2022;45:685-698.
    >> Share

    May 2022
  28. MARTIN GL, Jouganous J, Savidan R, Bellec A, et al
    Validation of Artificial Intelligence to Support the Automatic Coding of Patient Adverse Drug Reaction Reports, Using Nationwide Pharmacovigilance Data.
    Drug Saf. 2022;45:535-548.
    >> Share

    April 2022
  29. KANT A, Jansen J, van Balveren L, van Hunsel F, et al
    Description of Frequencies of Reported Adverse Events Following Immunization Among Four Different COVID-19 Vaccine Brands.
    Drug Saf. 2022;45:319-331.
    >> Share

    February 2022
  30. FERNER RE, Stevens RJ, Anton C, Aronson JK, et al
    Spontaneous Reporting to Regulatory Authorities of Suspected Adverse Drug Reactions to COVID-19 Vaccines Over Time: The Effect of Publicity.
    Drug Saf. 2022;45:137-144.
    >> Share

    December 2021
  31. LUXI N, Giovanazzi A, Capuano A, Crisafulli S, et al
    COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients, and Persons with History of Allergy or Prior SARS-CoV-2 Infection: Overview of Current Recommendations and Pre- and Post-Marketing Evidence for Vaccine Efficacy and Safety.
    Drug Saf. 2021;44:1247-1269.
    >> Share

    November 2021
  32. CLINTON JW, Kiparizoska S, Aggarwal S, Woo S, et al
    Drug-Induced Liver Injury: Highlights and Controversies in the Recent Literature.
    Drug Saf. 2021;44:1125-1149.
    >> Share

  33. IGUCHI T, Umeda H, Kojima M, Kanno Y, et al
    Cumulative Adverse Event Reporting of Anaphylaxis After mRNA COVID-19 Vaccine (Pfizer-BioNTech) Injections in Japan: The First-Month Report.
    Drug Saf. 2021;44:1209-1214.
    >> Share

    October 2021
  34. SALAMANCA DE LA CUEVA I, Cinconze E, Eckermann T, Nwoji U, et al
    Safety Profile of GSK's Inactivated Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany and Spain: Passive Enhanced Safety Surveillance Study for the 2019/2020 Influenza Season.
    Drug Saf. 2021 Oct 25. pii: 10.1007/s40264-021-01121.
    >> Share

    September 2021
  35. ROCCA E, Gauffin O, Savage R, Vidlin SH, et al
    Remdesivir in the COVID-19 Pandemic: An Analysis of Spontaneous Reports in VigiBase During 2020.
    Drug Saf. 2021;44:987-998.
    >> Share

  36. MOORE N, Bosco-Levy P, Thurin N, Blin P, et al
    NSAIDs and COVID-19: A Systematic Review and Meta-analysis.
    Drug Saf. 2021;44:929-938.
    >> Share

    June 2021
  37. BHOWMICK S, Dang A, Vallish BN, Dang S, et al
    Safety and Efficacy of Ivermectin and Doxycycline Monotherapy and in Combination in the Treatment of COVID-19: A Scoping Review.
    Drug Saf. 2021;44:635-644.
    >> Share

    April 2021
  38. DASGUPTA N
    Safety Consequences of Off-Label Drugs Used for COVID-19.
    Drug Saf. 2021;44:399-402.
    >> Share

  39. GRANDVUILLEMIN A, Drici MD, Jonville-Bera AP, Micallef J, et al
    French Pharmacovigilance Public System and COVID-19 Pandemic.
    Drug Saf. 2021;44:405-408.
    >> Share

    February 2021
  40. MARZOLINI C, Stader F, Leuppi-Taegtmeyer A, Stoeckle M, et al
    Sex Differences in Lopinavir Concentrations and Occurrence of Marked QTc Prolongation Episodes in Patients with COVID-19.
    Drug Saf. 2021;44:255-257.
    >> Share

    January 2021
  41. BEYZAROV E, Chen Y, Julg R, Naim K, et al
    Global Safety Database Summary of COVID-19-Related Drug Utilization-Safety Surveillance: A Sponsor's Perspective.
    Drug Saf. 2021;44:95-105.
    >> Share

  42. SHAKIR S, Lane S, Davies M
    How to Investigate a Serious Adverse Event Reported During a Clinical Trial for a COVID-19 Vaccine.
    Drug Saf. 2021;44:1-5.
    >> Share

    December 2020
  43. GARCIA P, Revet A, Yrondi A, Rousseau V, et al
    Psychiatric Disorders and Hydroxychloroquine for Coronavirus Disease 2019 (COVID-19): A VigiBase Study.
    Drug Saf. 2020;43:1315-1322.
    >> Share

  44. PETOUSIS-HARRIS H
    Assessing the Safety of COVID-19 Vaccines: A Primer.
    Drug Saf. 2020;43:1205-1210.
    >> Share

  45. ZEKARIAS A, Watson S, Vidlin SH, Grundmark B, et al
    Sex Differences in Reported Adverse Drug Reactions to COVID-19 Drugs in a Global Database of Individual Case Safety Reports.
    Drug Saf. 2020;43:1309-1314.
    >> Share

  46. TRIFIRO G, Massari M, Da Cas R, Menniti Ippolito F, et al
    Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Death in Patients Hospitalised with COVID-19: A Retrospective Italian Cohort Study of 43,000 Patients.
    Drug Saf. 2020;43:1297-1308.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016